Amgen Tax Official Describes Importance Of Fully Describing Company, Transfer Pricing at Audit

An Amgen Inc. official March 1 suggested that it is best to take the time to fully describe a company’s transfer pricing to auditors rather that just lobbing a thick binder of documentation over the wall to the Internal Revenue Service when the documents are requested.

Amgen’s tax department produces picture- and chart-laden slides, tours of manufacturing plants, and offers interviews with senior personnel in numerous departments to explain the multinational biotechnology company’s intercompany pricing, according to Kevin O’Toole, Amgen’s executive director for tax. Enjoying this article? To continue reading you need to take out a FREE trial to the Transfer Pricing Library.




Already a subscriber? Sign in here

Related Articles:

• Scientific Instrument Company FEI Announces U.S.-Netherlands APA
• APA Officials Discuss New Procedures Including Scrutiny of Unilateral Submissions
• First MAP for automotive industry
• Mexico’s SAT Appeals First-Ever Ruling For Taxpayer in Transfer Pricing Trial
• Tipping the Balance in Favour of APAs – the US Experience